Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper
European Journal of Neurology · 2026-09 · 33 (9)
DOI: 10.1111/ene.70747 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Neurology, online erschienen am 09.09.2026. Verfasst von Andreas Meisel und 17 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-…. Hauptthemen laut MEDLINE: Myasthenia Gravis, Immunotherapy. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Alexion Pharmaceuticals.
Abstract (Originalsprache)
Background
The therapeutic landscape of generalised myasthenia gravis (gMG) has evolved substantially with the approval of targeted immunotherapies, including complement C5 inhibitors (C5‐I) and neonatal Fc receptor inhibitors (FcRn‐I). While pivotal trials have demonstrated marked efficacy in defined subgroups, real‐world experience reveals more heterogeneous outcomes and raises questions about optimal patient selection, therapy sequencing and integration into clinical practice. In Germany and Austria, early access following regulatory approval has facilitated clinical experience over recent years. This expert opinion paper aims to combine current evidence with clinical experience to guide the use of C5‐I and FcRn‐I in everyday care.
Methods
A panel of 18 neurologists from Germany and Austria, including two paediatric neurologists, evaluated study data and real‐world experiences. Through structured discussion and a consensus process, they developed evidence‐ and experience‐based recommendations on integrating targeted immunotherapies into existing treatment algorithms.
Results
The panel provides practical recommendations for managing (highly) active gMG in adults, focusing on C5‐I (eculizumab, ravulizumab, zilucoplan) and FcRn‐I (efgartigimod, rozanolixizumab). The statements cover initiation criteria, sequencing and switching within and between drug classes and transitions to intensified immunomodulatory therapies (rituximab, apheresis, intravenous or subcutaneous immunoglobulin), as well as special considerations for juvenile MG.
Conclusions
This expert statement provides a practice‐oriented framework integrating current evidence and clinical experience to support individualised therapeutic decision‐making in gMG.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurology With Experimental Neurology, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Neuroscience Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
- Department of Pediatric Neurology, Center for Neuromuscular Disorders in Children and Adolescents, University Hospital Essen, University Duisburg-Essen, Essen, Germany.
- Department of Neurology and Center for Translational Neuro- and Behavioral Sciences (C-TNBS), University Hospital Essen, Essen, Germany.
- Department of Neurology, Justus-Liebig-University Giessen, Giessen, Germany.
ORCID-Profile: Andreas Meisel, Paolo Doksani, Tim Hagenacker, Heidrun H Krämer, Jan D Lünemann, Tobias Ruck, Benedikt Schoser, Charlotte Schubert, Fritz Zimprich, Jana Zschüntzsch, Sarah Hoffmann
Förderung
- Alexion Pharmaceuticals
Zitieren
APA
Meisel, A., Marina, A. D., Doksani, P., Hagenacker, T., Kleinschnitz, C., Krämer, H. H., Lünemann, J. D., Meuth, S. G., Ruck, T., Schara-Schmidt, U., Schneider-Gold, C., Schoser, B., Schroeter, M., Schubert, C., Sieb, J. P., Zimprich, F., Zschüntzsch, J., & Hoffmann, S. (2026). Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper. European Journal of Neurology, 33(9). https://doi.org/10.1111/ene.70747
Vancouver
Meisel A, Marina AD, Doksani P, Hagenacker T, Kleinschnitz C, Krämer HH, et al. Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper. European Journal of Neurology. 2026;33(9). doi:10.1111/ene.70747
BibTeX
@article{Meisel2026,
author = {Meisel, Andreas and Marina, Adela Della and Doksani, Paolo and Hagenacker, Tim and Kleinschnitz, Christoph and Krämer, Heidrun H and Lünemann, Jan D and Meuth, Sven G and Ruck, Tobias and Schara-Schmidt, Ulrike and Schneider-Gold, Christiane and Schoser, Benedikt and Schroeter, Michael and Schubert, Charlotte and Sieb, Jörn Peter and Zimprich, Fritz and Zschüntzsch, Jana and Hoffmann, Sarah},
title = {Practical Guidance on Initiating and Switching Targeted Immunotherapies in Generalised Myasthenia Gravis: A German–Austrian Expert Opinion Paper},
journal = {European Journal of Neurology},
year = {2026},
volume = {33},
number = {9},
doi = {10.1111/ene.70747}
}
EUVIMED